Compare NOVT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOVT | IMVT |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.0B |
| IPO Year | 1999 | 2019 |
| Metric | NOVT | IMVT |
|---|---|---|
| Price | $117.04 | $25.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $133.00 | $30.78 |
| AVG Volume (30 Days) | 393.7K | ★ 896.5K |
| Earning Date | 05-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $521,290,000.00 | N/A |
| Revenue This Year | $8.71 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $79.34 | ★ N/A |
| Revenue Growth | ★ 35.49 | N/A |
| 52 Week Low | $98.27 | $12.72 |
| 52 Week High | $149.95 | $29.25 |
| Indicator | NOVT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 40.52 |
| Support Level | $111.49 | $24.63 |
| Resistance Level | $126.36 | $27.71 |
| Average True Range (ATR) | 6.39 | 1.17 |
| MACD | -2.56 | -0.30 |
| Stochastic Oscillator | 10.88 | 15.90 |
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.